The neuroprotective potential of MIS416, a myeloid-directed innate immune therapeutic in Phase 2B trial for the treatment of secondary progressive multiple sclerosis

首页> 外文期刊>Multiple sclerosis: clinical and laboratory research >The neuroprotective potential of MIS416, a myeloid-directed innate immune therapeutic in Phase 2B trial for the treatment of secondary progressive multiple sclerosis

【24h】

The neuroprotective potential of MIS416, a myeloid-directed innate immune therapeutic in Phase 2B trial for the treatment of secondary progressive multiple sclerosis

机译：MIS416的神经保护潜能，它是2B期临床试验中由髓样定向的先天性免疫治疗药物，用于治疗继发性进行性多发性硬化症

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Multiple sclerosis: clinical and laboratory research 》 |2015年第14期| 共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类神经病学与精神病学 ;
关键词
Myeloid-directed; neuroprotection; kynurenine/tryptophan; growth-factors; anti-inflammatory;

机译：髓样定向;神经保护;犬尿氨酸/色氨酸;生长因子;抗炎;

相似文献

外文文献
中文文献
专利

1. The neuroprotective potential of MIS416, a myeloid-directed innate immune therapeutic in Phase 2B trial for the treatment of secondary progressive multiple sclerosis [J] . Multiple sclerosis: clinical and laboratory research . 2015 ,第14期

机译：MIS416的神经保护潜能，它是2B期临床试验中由髓样定向的先天性免疫治疗药物，用于治疗继发性进行性多发性硬化症
2. Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple scl [J] . Peter Connick, Floriana De Angelis, Richard A Parker, BMJ Open . 2018 ,第8期

机译：多发性硬化症-进行性多臂继发性随机试验（MS-SMART）：一项多臂IIb期随机，双盲，安慰剂对照的临床试验，比较了三种神经保护药在继发性进行性多发性硬化中的疗效
3. Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis [J] . Stanley L. Cohan, Elisabeth B. Lucassen, Meghan C. Romba, Biomedicines . 2019 ,第1期

机译：达克珠单抗：作用机制，疗效，不良事件及其发现先天免疫系统募集作为复发性多发性硬化症的治疗策略的潜在作用
4. Developing Diagnostic Biomarkers for Secondary Progressive Multiple Sclerosis using Selected Reaction Monitoring [C] . Yan Jia, Christine Jelinek, Scott Newsome, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2011

机译：使用选定的反应监测开发二次逐步多发性硬化的诊断生物标志物
5. Magnetic resonance imaging evaluation and therapeutic trials in primary progressive multiple sclerosis. [D] . Leary, Siobhan Marie. 2002

机译：原发性进行性多发性硬化症的磁共振成像评估和治疗试验。
6. Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis [O] . Peter Connick, Floriana De Angelis, Richard A Parker, 1983

机译：多发性硬化症-进行性多臂继发性随机试验（MS-SMART）：一项多臂IIb期随机，双盲，安慰剂对照的临床试验，比较了三种神经保护药在继发性进行性多发性硬化症中的疗效
7. Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response [O] . Arnon Karni, Michal Abraham, Alon Monsonego, 2006

机译：多发性硬化症的先天免疫：继发性进行性多发性硬化症中的髓样树突状细胞被激活并促进促炎症免疫反应

The neuroprotective potential of MIS416, a myeloid-directed innate immune therapeutic in Phase 2B trial for the treatment of secondary progressive multiple sclerosis

著录项

相似文献

相关主题

期刊订阅